|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
159,588 |
275,693 |
319,053 |
656,089 |
Total Sell Value |
$13,270,852 |
$23,760,160 |
$27,661,182 |
$61,420,002 |
Total People Sold |
5 |
6 |
7 |
7 |
Total Sell Transactions |
10 |
21 |
27 |
56 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Wood Mark |
VP, Human Resources |
|
2011-11-22 |
4 |
OE |
$14.39 |
$32,920 |
D/D |
1,855 |
22,489 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2011-11-14 |
4 |
GA |
$0.00 |
$0 |
I/I |
333 |
4,482 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2011-11-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
333 |
56,106 |
|
- |
|
Cooper Jeffrey H |
SVP, Chief Financial Officer |
|
2011-11-01 |
4 |
AS |
$33.26 |
$83,145 |
D/D |
(2,500) |
40,104 |
|
- |
|
Cooper Jeffrey H |
SVP, Chief Financial Officer |
|
2011-11-01 |
4 |
OE |
$14.39 |
$35,975 |
D/D |
2,500 |
42,604 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2011-11-01 |
4 |
AS |
$33.23 |
$8,641 |
D/D |
(260) |
39,651 |
|
- |
|
Aselage Steve |
EVP, Chief Business Officer |
|
2011-10-31 |
5 |
B |
$13.23 |
$2,658 |
D/D |
201 |
46,679 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2011-10-31 |
5 |
B |
$13.23 |
$12,750 |
D/D |
964 |
8,300 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2011-10-31 |
5 |
B |
$13.26 |
$4,416 |
D/D |
333 |
83,493 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2011-10-31 |
4 |
A |
$13.23 |
$2,063 |
D/D |
156 |
36,611 |
|
- |
|
Cooper Jeffrey H |
SVP, Chief Financial Officer |
|
2011-10-31 |
4 |
A |
$13.23 |
$3,016 |
D/D |
228 |
40,104 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2011-10-31 |
4 |
A |
$13.23 |
$3,439 |
D/D |
260 |
39,911 |
|
- |
|
Aselage Steve |
EVP, Chief Business Officer |
|
2011-10-28 |
4 |
AS |
$35.00 |
$590,625 |
D/D |
(16,875) |
46,478 |
|
- |
|
Aselage Steve |
EVP, Chief Business Officer |
|
2011-10-28 |
4 |
OE |
$14.39 |
$242,831 |
D/D |
16,875 |
63,353 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2011-10-24 |
4 |
AS |
$33.32 |
$61,750 |
D/D |
(1,853) |
20,634 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2011-10-24 |
4 |
OE |
$14.39 |
$32,884 |
D/D |
1,853 |
22,487 |
|
- |
|
Cooper Jeffrey H |
SVP, Chief Financial Officer |
|
2011-10-10 |
4 |
AS |
$34.00 |
$624,886 |
D/D |
(18,379) |
39,876 |
|
- |
|
Cooper Jeffrey H |
SVP, Chief Financial Officer |
|
2011-10-10 |
4 |
OE |
$17.54 |
$322,368 |
D/D |
18,379 |
58,255 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2011-10-03 |
4 |
AS |
$31.00 |
$77,507 |
D/D |
(2,500) |
36,455 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2011-10-03 |
4 |
OE |
$11.05 |
$27,625 |
D/D |
2,500 |
38,955 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2011-09-28 |
4 |
AS |
$32.00 |
$32,000 |
D/D |
(1,000) |
126,093 |
|
- |
|
Cooper Jeffrey H |
SVP, Chief Financial Officer |
|
2011-09-28 |
4 |
AS |
$32.00 |
$588,128 |
D/D |
(18,379) |
39,876 |
|
- |
|
Cooper Jeffrey H |
SVP, Chief Financial Officer |
|
2011-09-28 |
4 |
OE |
$17.54 |
$322,368 |
D/D |
18,379 |
58,255 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2011-09-22 |
4 |
AS |
$29.92 |
$55,472 |
D/D |
(1,854) |
20,634 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2011-09-22 |
4 |
OE |
$14.39 |
$32,898 |
D/D |
1,854 |
22,488 |
|
- |
|
1283 Records found
|
|
Page 23 of 52 |
|
|